I've read through the original lancet article (well, skimmed through it to be honest) and it seems to be a small effect. Significant but on the lower end of the spectrum. Nevertheless that is some exciting development. I'm particularly impressed by the vector used. Plasmids encapsuled in liposomes is a pretty great idea. Especially since virus vectors do not work very well in the lungs due to very strong immunoactivity. I really hope that further trials can build on that and maybe even improve FEV (forced expiratory volume, a measurement of how much air you can exhale in 1s) instead of just stabilizing it.
I've read through the original lancet article (well, skimmed through it to be honest) and it seems to be a small effect. Significant but on the lower end of the spectrum. Nevertheless that is some exciting development. I'm particularly impressed by the vector used. Plasmids encapsuled in liposomes is a pretty great idea. Especially since virus vectors do not work very well in the lungs due to very strong immunoactivity. I really hope that further trials can build on that and maybe even improve FEV (forced expiratory volume, a measurement of how much air you can exhale in 1s) instead of just stabilizing it.
Yeah, you're right. It's a good start though - I imagine they had to play it safe just to establish any side effects etc.